COMPANY PROFILE

TECregen

Explore full profile

Ligand-based therapies to restore thymus function and support lifelong immune health

Basel, SwitzerlandFounded 2023Biotech & Life Sciences

Valuation $50–100M Last recorded · 2026

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

At a glance

Status: Operational
Founded: 2023
Headquarters: Basel, Switzerland
Employees: 14
Open positions: None listed
Dealroom signal: 56.4/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Cardiology and cardiovascular, Immune System, Spinout, Biotech and Pharma, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

2 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SEED✓Equity / VC	Jan 2026	$13M	$50M	CARMA FUND Management · EOS Bioinnovation · Boehringer Ingelheim · HTGF	↗
SPINOUT✓Other financing	Jan 2023	$0	—	University of Basel	—

Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

TECregen website traffic

Latest recorded traffic for TECregen is 420 monthly website visits, down 30% over the last three months. TECregen's team grew 100% over the past year.

Latest monthly visits420 3-month web change-30% 1-year team growth+100%

Monthly website visitsJul 2025–Feb 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
CTCimeio TherapeuticsDeveloping Shielded-Cell & Drug Pairs to increase cure rates for patients with hematologic malignancies, genetic and autoimmune diseases	Cambridge, United States	Operational	16	$50M	$200M
HEHemastatxAntibody therapies targeting VWF-related bleeding disorders, leveraging scientific research and clinical innovation	Allschwil, Switzerland	Operational
NANanoPhoriaNon-viral nanoparticle drug delivery platform for cardiovascular treatments	Milan, Italy	Operational
STStratus TherapeuticsDeveloping off-the-shelf hematopoietic stem cell (HSC) therapies to treat a broad range of severe and life-threatening diseases	Natick, United States	Operational
BTBright Peak TherapeuticsDeveloping next-generation immunotherapies, focusing on the treatment of cancer and autoimmune diseases	Basel, Switzerland	Operational
EREna RespiratoryNasal spray boosting innate immunity against viruses	Melbourne, Australia	Operational
EHEdifice HealthOffers inflammatory health monitoring tests to help manage chronic inflammation and improve overall health and longevity	San Mateo, United States	Operational
DEDesentumBiopharma company in Finland developing allergy vaccines that change the way the immune system reacts to allergens	Espoo, Finland	Operational